Metabolomic Signatures in Cancer
A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".
Deadline for manuscript submissions: 20 August 2026 | Viewed by 292
Special Issue Editors
Interests: metabolomic; cancer; polyphenols; neuropathic pain
Interests: NMR- and MS-based metabolomics; cancer and immune cell metabolism; chronic kidney disease; gut microbiota and immunity; bioinformatics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Metabolomics has emerged as a pivotal field in cancer research, offering unprecedented insights into the altered metabolic pathways that drive oncogenesis, progression, and treatment response. This Special Issue of Metabolites, "Metabolomic Signatures in Cancer," seeks to compile high-quality original research and comprehensive review articles that explore the discovery and validation of novel metabolic biomarkers. We welcome contributions that utilize cutting-edge analytical platforms (e.g., MS, NMR) to characterize metabolic reprogramming in various cancers, investigate the tumor microenvironment, and explore the integration of metabolomics with other omics data for a holistic understanding of cancer biology. Studies focusing on the translational potential of metabolomic signatures for early detection, prognosis, and monitoring therapeutic efficacy are particularly encouraged. This collection aims to highlight the critical role of metabolomics in advancing personalized cancer medicine and improving patient outcomes.
Dr. Michael Daniel
Prof. Dr. Peter Oefner
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer metabolomics
- metabolic reprogramming
- biomarker discovery
- tumor microenvironment
- metabolic signatures
- therapeutic response
- early detection
- mass spectrometry
- NMR spectroscopy
- multi-omics integration
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
